Rebuilding Big Pharma R&D: An Interview With GSK’s Ian Tomlinson
Executive Summary
GlaxoSmithKline’s DPU model is industry’s most radical attempt to apply the lessons – and the pressures – of working in small biotech environments. BD and biopharma head Ian Tomlinson discusses what went wrong, and what GSK thinks it’s now doing right.
You may also be interested in...
J.P. Morgan Notebook: Thursday, January 16
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.
Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings
More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.
How GSK Is Driving Early Stage Research In Its DPUs
Most of GlaxoSmithKline's early stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.